L16 Therapeutics of Asthma

Description

PHCY310 Quiz on L16 Therapeutics of Asthma, created by Mer Scott on 12/04/2019.
Mer Scott
Quiz by Mer Scott, updated more than 1 year ago
Mer Scott
Created by Mer Scott over 5 years ago
9
0

Resource summary

Question 1

Question
Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.
Answer
  • True
  • False

Question 2

Question
Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.
Answer
  • True
  • False

Question 3

Question
When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of [blank_start]signs and symptoms[blank_end](wheezing, breathlessness, chest tightness, and coughing, particularly at [blank_start]night[blank_end] or [blank_start]early[blank_end] in the morning). We can also measure [blank_start]expiratory airflow[blank_end] on more than one occasion, and assess [blank_start]response[blank_end] to inhaled bronchodilator +/- inhaled corticosteroid.
Answer
  • signs and symptoms
  • night
  • early
  • expiratory airflow
  • response

Question 4

Question
Ideal PEFR values depend on height and sex.
Answer
  • True
  • False

Question 5

Question
Which of these is NOT a principle of asthma treatment?
Answer
  • Avoid triggers
  • Making an asthma plan
  • Drugs to improve ventilation
  • Drugs to decrease inflammation
  • Avoid exercise

Question 6

Question
Goals of asthma treatment are about maintaining long-term control using the [blank_start]least[blank_end] amount of medications and [blank_start]minimising[blank_end] adverse effects. We want to prevent chronic [blank_start]symptoms[blank_end], require infrequent use ([blank_start]2[blank_end] or fewer days/week) of SABA, maintain normal or near-normal [blank_start]pulmonary[blank_end] function and maintain [blank_start]activity[blank_end] levels. We should assure patients’ and families’ [blank_start]satisfaction[blank_end] with asthma care. We also want to prevent exacerbations, the need for [blank_start]hospitalisation[blank_end], and prevent progressive [blank_start]loss[blank_end] of lung function.
Answer
  • least
  • minimising
  • symptoms
  • 2
  • pulmonary
  • activity
  • satisfaction
  • hospitalisation
  • loss

Question 7

Question
Which of these is not a drug delivery device?
Answer
  • Soft mist inhaler (SMI) - only with LAMA products in NZ
  • Nebuliser
  • Dry power inhaler (DPI)
  • Metered-dose inhaler (MDI) - spacer chamber
  • Dry mist inhaler (DMI)

Question 8

Question
Treatment steps: 1. At initial diagnosis, all patients should use a [blank_start]SABA[blank_end], as required.. 2. Add an [blank_start]ICS[blank_end] if patients have symptoms for more than [blank_start]two[blank_end] weeks. Often a big decision! (The usual dose in adults is [blank_start]budesonide 400 mcg[blank_end]/day.) 3. If control is not adequate, [blank_start]ICS dose[blank_end] can be increased. 4. If control is not adequate, combine [blank_start]ICS with a LABA[blank_end]. ([blank_start]Formoterol+budesonide[blank_end] can be used as a preventer and replace SABA.) Patients can step up or down in order to achieve and maintain control. Check adherence and inhaler [blank_start]technique[blank_end] at each step of the way!
Answer
  • SABA
  • ICS
  • two
  • budesonide 400 mcg
  • ICS dose
  • ICS with a LABA
  • Formoterol+budesonide
  • technique
Show full summary Hide full summary

Similar

GCSE Geography Climate Change
EllieFlint
Command or Process Words for Essay Writing
Bekki
Compensation
Sandra Reed
Chemistry C2
greenchloe1998
AQA AS Biology Unit 2 The Cell cycle
elliedee
National 5 Biology: Cell Biology
Mhairi McCann
Geography Section 1 (Rivers and Coasts)
Beth Goodchild
Chemistry Rates of Reaction Revision
11mzroser
Forces and motion
Catarina Borges
The Circulatory System
Johnny Hammer